{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Acetyl choline", "Alzheimer's disease", "Amyloid-Beta (A\u03b2) plaques", "Clinical trials", "Herbal drugs", "Tau Protein Tangles"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36601504", "DateRevised": {"Year": "2023", "Month": "01", "Day": "11"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "10", "Day": "12"}], "Language": ["eng"], "ELocationID": ["10.1016/j.jsps.2022.10.004"], "Journal": {"ISSN": "1319-0164", "JournalIssue": {"Volume": "30", "Issue": "12", "PubDate": {"Year": "2022", "Month": "Dec"}}, "Title": "Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society", "ISOAbbreviation": "Saudi Pharm J"}, "ArticleTitle": "An update on the novel and approved drugs for Alzheimer disease.", "Pagination": {"StartPage": "1755", "EndPage": "1764", "MedlinePgn": "1755-1764"}, "Abstract": {"AbstractText": ["Given the severity of the condition and the increasing number of patients, developing effective therapies for Alzheimer's disease has become a significant necessity. Aggregation of Amyloid-Beta (A\u03b2) plaques and Tau Protein Tangles in the brain's nerve tissue are two of the most histopathological/pathophysiological symptoms. Another important element involved in the etiology of Alzheimer's disease is the reduction in acetylcholine (ACh) levels in the brain. Currently available medications for Alzheimer's disease treatment, such as cholinesterase inhibitors and an antagonist of the <i>N</i>-methyl-d-aspartate receptor, can temporarily reduce dementia symptoms but not stop or reverse disease development. In addition, several medicinal plants have been shown to diminish the degenerative characteristics associated with Alzheimer's disease, either in its crude form or as isolated chemicals.", "This review summarises the results from previous studies that reflect an array of novel therapies underway in various phases of clinical trials. Many are discontinued due to non-adherence to the designed endpoints or the surfacing of unavoidable side effects. The present piece of article focuses on the approved drugs for the treatment of Alzheimer's disease and their related mode of action as well as the promising therapies for the treatment of the said disease. Special attention has been placed on the researched herbal drugs, with the pipeline of novel therapies underway in various phases of clinical trials.", "The current article includes a list of approved pharmaceuticals for treating Alzheimer's disease, prospective therapies for the illness's treatment, and a pipeline of novel therapies in various stages of clinical trials.", "The results suggest that the drugs under clinical trials may open new pathways for the effective treatment of patients with Alzheimer's disease while improving their quality of life."], "CopyrightInformation": "\u00a9 2022 The Authors."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, P. Box No. 114, Jazan, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Substance Abuse and Toxicology Research Centre, Jazan University, P. Box No. 114, Jazan, Saudi Arabia."}], "LastName": "Alhazmi", "ForeName": "Hassan Ahmad", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, P. Box No. 114, Jazan, Saudi Arabia."}], "LastName": "Albratty", "ForeName": "Mohammed", "Initials": "M"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Saudi Arabia", "MedlineTA": "Saudi Pharm J", "NlmUniqueID": "9705695", "ISSNLinking": "1319-0164"}, "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Abdallah S.M., Zayed M., Mohamed G.G. Synthesis and spectroscopic characterization of new tetradentate Schiff base and its coordination compounds of NOON donor atoms and their antibacterial and antifungal activity. Arabian J. Chem. 2010;3:103\u2013113. doi: 10.1016/j.arabjc.2010.02.006.", "ArticleIdList": ["10.1016/j.arabjc.2010.02.006"]}, {"Citation": "Ahmed M., Malik M., Teselink J., Lanct\u00f4t K.L., Herrmann N. Current agents in development for treating behavioral and psychological symptoms associated with dementia. Drugs Aging. 2019;36(7):589\u2013605. doi: 10.1007/s40266-019-00668-7.", "ArticleIdList": ["10.1007/s40266-019-00668-7", "30957198"]}, {"Citation": "Anand A., Patience A.A., Sharma N., Khurana N. The present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review. Eur. J. Pharmacol. 2017;815:364\u2013375. doi: 10.1016/j.ejphar.2017.09.043.", "ArticleIdList": ["10.1016/j.ejphar.2017.09.043", "28978455"]}, {"Citation": "Ansari N., Khodagholi F. Natural products as promising drug candidates for the treatment of Alzheimer\u2019s disease: molecular mechanism aspect. Curr. Neuropharmacol. 2013;11:414\u2013429. doi: 10.2174/1570159X11311040005.", "ArticleIdList": ["10.2174/1570159X11311040005", "PMC3744904", "24381531"]}, {"Citation": "Arndt, J.W., Qian, F., Smith, B.A., Quan, C., Kilambi, K.P., Bush, M.W., Walz, T., Pepinsky, R.B., Bussiere, T., Hamann, S., Cameron, T.O., Weinreb., 2018. PH: Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta. Sci Rep. 8(1):6412. doi: 10.1038/s41598-018-24501-0", "ArticleIdList": ["PMC5913127", "29686315"]}, {"Citation": "Atri A. Current and future treatments in Alzheimer\u2019s disease. Semin. Neurol. 2019;39:227\u2013240. doi: 10.1055/s-0039-1678581.", "ArticleIdList": ["10.1055/s-0039-1678581", "30925615"]}, {"Citation": "Bandegi, A.R., Rashidy-Pour, A., Vafaei, A.A., Ghadrdoost, B., 2014. Protective Effects of Crocus Sativus L. Extract and Crocin against Chronic-Stress Induced Oxidative Damage of Brain, Liver and Kidneys in Rats. Adv Pharm Bull. 4:493-499. https://dx.doi.org/10.5681%2Fapb.2014.073.", "ArticleIdList": ["PMC4312396", "25671180"]}, {"Citation": "Bendova P., Mackova E., Haskova P., Vavrova A., Jirkovsky E., Sterba M., Popelova O., Kalinowski D.S., Kovarikova P., Vavrova K. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem. Res. Toxicol. 2010;23:1105\u20131114. doi: 10.1021/tx100125t.", "ArticleIdList": ["10.1021/tx100125t", "20521781"]}, {"Citation": "Biasibetti R., Tramontina A.C., Costa A.P., Dutra M.F., QuincozesSantos A., Nardin P. Green tea (\u2212) epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia. Behav. Brain Res. 2013;236:186\u2013193. doi: 10.1016/j.bbr.2012.08.039.", "ArticleIdList": ["10.1016/j.bbr.2012.08.039", "22964138"]}, {"Citation": "Bihaqui S.W., Singh A.P., Tiwari M. Supplementation of Convolvulus pluricaulis attenuates scopolamine-induced increased tau and Amyloid precursor protein (A\u03b2PP) expression in rat brain. Indian J. Pharmacol. 2012;44:593. doi: 10.4103/0253-7613.100383.", "ArticleIdList": ["10.4103/0253-7613.100383", "PMC3480791", "23112420"]}, {"Citation": "Bishop G.M., Robinson S.R. Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease. Drugs Aging. 2004;21(10):621\u2013630. doi: 10.2165/00002512-200421100-00001.", "ArticleIdList": ["10.2165/00002512-200421100-00001", "15287821"]}, {"Citation": "Bondi M.W., Edmonds E.C., Salmon D.P. Alzheimer\u2019s disease: past, present, and future. J. Int. Neuropsychol. Soc. 2017;23:818\u2013831. doi: 10.1017/s135561771700100x.", "ArticleIdList": ["10.1017/s135561771700100x", "PMC5830188", "29198280"]}, {"Citation": "Budimir A. Metal ions, Alzheimer's disease, and chelation therapy. Acta Pharm. 2011;61:1\u201314. doi: 10.2478/v10007-011-0006-6.", "ArticleIdList": ["10.2478/v10007-011-0006-6", "21406339"]}, {"Citation": "Calv\u00f3-Perxas L., Turr\u00f3-Garriga O., Vilalta-Franch J., Lozano-Gallego M., de Eugenio R., M\u00e1rquez F., Carmona O., Gich J., Manzano A., Vi\u00f1as M., Roig A.M., Garre-Olmo J. Trends in the prescription and long-term utilization of antidementia drugs among patients with Alzheimer's disease in Spain: a cohort study using the registry of dementias of girona. registry of dementias of girona study group (ReDeGi Study Group) Drugs Aging. 2017;34(4):303\u2013310. doi: 10.1007/s40266-017-0446-x.", "ArticleIdList": ["10.1007/s40266-017-0446-x", "28258538"]}, {"Citation": "Chakravarthi K.K., Avadhani R. Beneficial effect of aqueous root extract of Glycyrrhiza glabra on learning and memory using different behavioral models: an experimental study. J. Nat. Sci. Biol. Med. 2013;420\u2013425 doi: 10.4103/0976-9668.117025.", "ArticleIdList": ["10.4103/0976-9668.117025", "PMC3783792", "24082744"]}, {"Citation": "Chang X., Rong C., Chen Y., Yang C., Hu Q., Mo Y. (\u2212)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer\u2019s disease model mice by upregulating neprilysin expression. Exp. Cell Res. 2015;334:136\u2013145. doi: 10.1016/j.yexcr.2015.04.004.", "ArticleIdList": ["10.1016/j.yexcr.2015.04.004", "25882496"]}, {"Citation": "Cho W.H., Park J.C., Kim D.H. ID1201, the ethanolic extract of the fruit of Melia toosendan ameliorates impairments in spatial learning and reduces levels of amyloid beta in 5XFAD mice. Neurosci. Lett. 2014;583:170\u2013175. doi: 10.1016/j.neulet.2014.09.036.", "ArticleIdList": ["10.1016/j.neulet.2014.09.036", "25281546"]}, {"Citation": "Clarke E.T., Martell A.E. Stabilities of 1,2-dimethyl-3-hydroxy-4-pyridinone chelates of divalent and trivalent metal ions. Inorg. Chim. Acta. 1992;191:57\u201363. doi: 10.1016/S0020-1693(00)80327-8.", "ArticleIdList": ["10.1016/S0020-1693(00)80327-8"]}, {"Citation": "Coleman P.J., Gotter A.L., Herring W.J., Winrow C.J., Renger J.J. The discovery of suvorexant, the first orexin receptor drug for insomnia. Annu. Rev. Pharmacol. Toxicol. 2017;57:509\u2013533. doi: 10.1146/annurev-pharmtox-010716-104837.", "ArticleIdList": ["10.1146/annurev-pharmtox-010716-104837", "27860547"]}, {"Citation": "Coric V., Salloway S., Van Dyck C.H. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol. 2015;72:1324\u20131333. doi: 10.1001/jamaneurol.2015.0607.", "ArticleIdList": ["10.1001/jamaneurol.2015.0607", "26414022"]}, {"Citation": "Cummings, J., Lee, G., Ritter, A., Sabbagh, M., Zhong, K., 2019.\u00a0Alzheimer\u2019s disease drug development pipeline: 2019\u00a0Alzheimers Dement. 5:272-293. https://doi.org/10.1016/j.trci.2019.05.008.", "ArticleIdList": ["PMC6617248", "31334330"]}, {"Citation": "Defeudis F.V. Bilobalide and neuroprotection. Pharmacol. Res. 2002;46:565\u2013568. doi: 10.1016/s1043-6618(02)00233-5.", "ArticleIdList": ["10.1016/s1043-6618(02)00233-5", "12457632"]}, {"Citation": "Deraeve, C., Pit\u00ede, M., Mazarguil, H., Meunier, B., 2007. Bis-8-hydroxyquinoline ligands as potential anti-Alzheimer agents, New J. Chem., 31, 193\u2013195. https://doi.org/10.1039/B616085A"}, {"Citation": "Doody R.S., Raman R., Farlow M. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N. Engl. J. Med. 2013;369:341\u2013350. doi: 10.1056/nejmoa1210951.", "ArticleIdList": ["10.1056/nejmoa1210951", "23883379"]}, {"Citation": "Dunstan R., Bussiere T., Engber T., Weinreb P., Maier M., Grimm J., Rhodes K., Arastu M., Li M., Zhang X. The role of brain macrophages on the clearance of amyloid plaques following the treatment of Tg2576 with BIIB037. Alzheimers Dement. l. 2011;7(4):S700. doi: 10.1016/j.jalz.2011.05.2025.", "ArticleIdList": ["10.1016/j.jalz.2011.05.2025"]}, {"Citation": "Egan M.F., Kost J., Voss T. Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N. Engl. J. Med. 2019;380:1408\u20131420. doi: 10.1056/NEJMoa1812840.", "ArticleIdList": ["10.1056/NEJMoa1812840", "PMC6776078", "30970186"]}, {"Citation": "Ferrada, V., Arancibia, B., Loeb, E., Norambuena, C., OleaAzar., Huidobro-Toro, J.P., 2007. Neurotoxicology. 28, 445\u2013449. https://doi.org/10.1016/j.neuro.2007.02.004.", "ArticleIdList": ["17382398"]}, {"Citation": "Ferrero J., Williams L., Stella H., Leitermann K., Mikulskis A., O'Gorman J., Sevigny J. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease. Alzheimers Dement (N Y) 2016;2(3):169\u2013176. doi: 10.1016/j.trci.2016.06.002.", "ArticleIdList": ["10.1016/j.trci.2016.06.002", "PMC5651340", "29067304"]}, {"Citation": "Francis P. The interplay of neurotransmitters in Alzheimer's disease. CNS Spectrums. 2005;10(S18):6\u20139. doi: 10.1017/S1092852900014164.", "ArticleIdList": ["10.1017/S1092852900014164", "16273023"]}, {"Citation": "Galimberti D., Scarpini E. Pioglitazone for the treatment of Alzheimer\u2019s disease. Expert. Opin. Investig. Drugs. 2017;26(1):97\u2013101. doi: 10.1080/13543784.2017.1265504.", "ArticleIdList": ["10.1080/13543784.2017.1265504", "27885860"]}, {"Citation": "Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u2013356. doi: 10.1126/science.1072994.", "ArticleIdList": ["10.1126/science.1072994", "12130773"]}, {"Citation": "He Q., Sun J., Wang Q., Wang W., He B. Neuroprotective effects of ginsenoside Rg1 against oxygen-glucose deprivation in cultured hippocampal neurons. J. Chin. Med. Assoc. 2014;77:142\u2013149. doi: 10.1016/j.jcma.2014.01.001.", "ArticleIdList": ["10.1016/j.jcma.2014.01.001", "24548377"]}, {"Citation": "Henley D., Raghavan N., Sperling R., Aisen P., Raman R., Romano G. Preliminary results of a trial of atabecestat in preclinical Alzheimer\u2019s disease. N. Engl. J. Med. 2019;380:1483\u20131485. doi: 10.1056/nejmc1813435.", "ArticleIdList": ["10.1056/nejmc1813435", "30970197"]}, {"Citation": "Herring W.J., Roth T., Krystal A.D., Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J. Sleep Res. 2019;28(2):e12782. doi: 10.1111/jsr.12782.", "ArticleIdList": ["10.1111/jsr.12782", "30338596"]}, {"Citation": "Hoi C.P., Ho Y.P., Baum L., Chow A.H.L. Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta-amyloid-induced toxicity in PC12 cells. Phytother. Res. 2010;24:1538\u20131542. doi: 10.1002/ptr.3178.", "ArticleIdList": ["10.1002/ptr.3178", "20878707"]}, {"Citation": "Huang L.K., Chao S.P., Hu C.J. Clinical trials of new drugs for Alzheimer disease. J. Biomed. Sci. 2020;27:18. doi: 10.1186/s12929-019-0609-7.", "ArticleIdList": ["10.1186/s12929-019-0609-7", "PMC6943903", "31906949"]}, {"Citation": "Huang M., Jiang X., Liang Y., Liu Q., Chen S., Guo Y. Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of \u03b2-amyloid in APP/ tau/PS1 mouse model of Alzheimer\u2019s disease. Exp. Gerontol. 2017;91:25\u201333. doi: 10.1016/j.exger.2017.02.004.", "ArticleIdList": ["10.1016/j.exger.2017.02.004", "28223223"]}, {"Citation": "Hull M., Sadowsky C., Arai H. Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer\u2019s disease. Curr. Alzheimer Res. 2017;14:696\u2013708. doi: 10.2174/1567205014666170117101537.", "ArticleIdList": ["10.2174/1567205014666170117101537", "PMC5543567", "28124589"]}, {"Citation": "Jeong E.J., Hwang L., Lee M., Lee K.Y., Ahn M.J., Sung S.H. Neuroprotective biflavonoids of Chamaecyparis obtusa leaves against glutamate-induced oxidative stress in HT22 hippocampal cells. Food Chem. Toxicol. 2014;64:397\u2013402. doi: 10.1016/j.fct.2013.12.003.", "ArticleIdList": ["10.1016/j.fct.2013.12.003", "24315869"]}, {"Citation": "Kishita N., Backhouse T., Mioshi E.J. Nonpharmacological interventions to improve depression, anxiety, and quality of life (QoL) in people with Dementia: an overview of systematic reviews. Geriatr. Psychiatry Neurol. 2020;33(1):28\u201341. doi: 10.1177/0891988719856690.", "ArticleIdList": ["10.1177/0891988719856690", "31203712"]}, {"Citation": "Krishnankutty., John, V., 2003. Synthesis, Characterization, and Antitumour Studies of Metal Chelates of Some Synthetic Curcuminoids Synth. React. Inorg. Met. Org. Chem. 33, 343\u2013358. https://doi.org/10.1081/SIM-120017791"}, {"Citation": "Lautenschl\u00e4ger M., Sendker J., H\u00fcwel S., Galla H.J., Brandt S., D\u00fcfer M. Intestinal formation of trans-crocetin from saffron extract (Crocus sativus L.) and in vitro permeation through intestinal and blood brain barrier. Phytomedicine. 2015;22:36\u201344. doi: 10.1016/j.phymed.2014.10.009.", "ArticleIdList": ["10.1016/j.phymed.2014.10.009", "25636868"]}, {"Citation": "Lawlor B., Segurado R., Kennelly S., Rikkert M.G.O., Howard R., Pasquier F. Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial. PLoS Med. 2018;15(9):e1002660. doi: 10.1371/journal.pmed.1002660.", "ArticleIdList": ["10.1371/journal.pmed.1002660", "PMC6152871", "30248105"]}, {"Citation": "Lee J.W., Lee Y.K., Ban J.O., Ha T.Y., Yun Y.P., Han S.B. Green tea (-)-epigallocatechin-3-gallate inhibits \u03b2-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-\u03baB pathways in mice. J. Nutr. 2009;139:1987\u20131993. doi: 10.3945/jn.109.109785.", "ArticleIdList": ["10.3945/jn.109.109785", "19656855"]}, {"Citation": "Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001;21:8370\u20138377. doi: 10.1523/jneurosci.21-21-08370.2001.", "ArticleIdList": ["10.1523/jneurosci.21-21-08370.2001", "PMC6762797", "11606625"]}, {"Citation": "Liu Y.R., Li P.W., Suo J.J., Sun Y., Zhang B.A., Lu H., Zhu H.C., Zhang G.B. Catalpol provides protective effects against cerebral ischaemia/reperfusion injury in gerbils. J. Pharm. Pharmacol. 2014;66:1265\u20131270. doi: 10.1111/jphp.12261.", "ArticleIdList": ["10.1111/jphp.12261", "24720795"]}, {"Citation": "Liu D., Zhang H., Gu W., Liu Y., Zhang M. Ginsenoside Rb1 protects hippocampal neurons from high glucose-induced neurotoxicity by inhibiting GSK3\u03b2-mediated CHOP induction. Mol. Med. Rep. 2014;9:1434\u20131438. doi: 10.3892/mmr.2014.1958.", "ArticleIdList": ["10.3892/mmr.2014.1958", "24535619"]}, {"Citation": "Lopez C., Tariot P.N., Caputo A. The Alzheimer\u2019s Prevention Initiative Generation Program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer\u2019s disease. Alzheimers Dement. 2019;5:216\u2013227. doi: 10.1016/j.trci.2019.02.005.", "ArticleIdList": ["10.1016/j.trci.2019.02.005", "PMC6562315", "31211217"]}, {"Citation": "Molinuevo J.L., Llad\u00f3 A., Rami L. Memantine: targeting glutamate excitotoxicity in Alzheimer\u2019s disease and other dementias. Am. J. Alzheimers Dis. Other Demen. 2005;20:77\u201385. doi: 10.1177/153331750502000206.", "ArticleIdList": ["10.1177/153331750502000206", "15844753"]}, {"Citation": "Muntimadugu E., Dhommati R., Jain A., Challa V.G., Shaheen M., Khan W. Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer\u2019s disease. Eur. J. Pharm. Sci. 2016;92:224\u2013234. doi: 10.1016/j.ejps.2016.05.012.", "ArticleIdList": ["10.1016/j.ejps.2016.05.012", "27185298"]}, {"Citation": "Murakami K., Irie K. Three structural features of functional food components and herbal medicine with amyloid \u03b242 anti-aggregation properties. Molecules. 2019;24(11):2125. doi: 10.3390/molecules24112125.", "ArticleIdList": ["10.3390/molecules24112125", "PMC6600243", "31195683"]}, {"Citation": "Olajide O.J., Yawson E.O., Gbadamosi I.T., Arogundade T.T., Lambe E., Obasi K. Ascorbic acid ameliorates behavioural deficits and neuropathological alterations in rat model of Alzheimer\u2019s disease. Environ. Toxicol. Pharmacol. 2017;50:200\u2013211. doi: 10.1016/j.etap.2017.02.010.", "ArticleIdList": ["10.1016/j.etap.2017.02.010", "28192749"]}, {"Citation": "Ostrowitzki S., Lasser R.A., Dorflinger E., Scheltens P., Barkhof F., Nikolcheva T., Ashford E., Retout S., Hofmann C., Delmar P., Klein G., Andjelkovic M., Dubois B., Boada M., Blennow K., Santarelli L., Fontoura P. SCarlet RoAD Investigators. a phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimers Res. Ther. 2017;9(1):95.", "ArticleIdList": ["PMC5723032", "29221491"]}, {"Citation": "Panza F., Seripa D., Lozupone M. The potential of solanezumab and gantenerumab to prevent Alzheimer\u2019s disease in people with inherited mutations that cause its early onset. Expert. Opin. Biol. Ther. 2018;18:25\u201335. doi: 10.1080/14712598.2018.1389885.", "ArticleIdList": ["10.1080/14712598.2018.1389885", "29037101"]}, {"Citation": "Pfaender S., Grabrucker A.M. Characterization of biometal profiles in neurological disorders. Metallomics. 2014;6:960\u2013977. doi: 10.1039/c4mt00008k.", "ArticleIdList": ["10.1039/c4mt00008k", "24643462"]}, {"Citation": "Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C.P. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63\u201375. doi: 10.1016/j.jalz.2012.11.007.", "ArticleIdList": ["10.1016/j.jalz.2012.11.007", "23305823"]}, {"Citation": "Rafii M., Walsh S., Little J., Behan K., Reynolds B., Ward C. A phase II trial of huperzine a in mild to moderate Alzheimer disease. Neurology. 2011;76(16):1389\u20131394. doi: 10.1212/wnl.0b013e318216eb7b.", "ArticleIdList": ["10.1212/wnl.0b013e318216eb7b", "PMC3269774", "21502597"]}, {"Citation": "Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., Mobius, HJ., 2003. Memantine in moderate-to-severe Alzheimer\u2019s disease. N. Engl. J. Med. 348, 1333\u20131341. http:// dx.doi.org/10.1056/NEJMoa013128.", "ArticleIdList": ["12672860"]}, {"Citation": "Ritchie, C.W., Bush, A.I., Mackinnon, A., Macfarlane,S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.X., Tammer A., 2003. Metal-Protein Attenuation with Iodochlorhydroxyquin (Clioquinol) Targeting A\u03b2 Amyloid Deposition and Toxicity in Alzheimer Disease. Arch. Neurol. 60, 1685\u20131691. 51 A. doi:10.1001/archneur.60.12.1685.", "ArticleIdList": ["14676042"]}, {"Citation": "Rountree S.D., Atri A., Lopez O.L., Doody R.S. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement. 2013;9(3):338\u2013345. doi: 10.1016/j.jalz.2012.01.002.", "ArticleIdList": ["10.1016/j.jalz.2012.01.002", "23102979"]}, {"Citation": "Salloway S., Sperling R., Keren R. ELND005-AD201 Investigators. a phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011;77:1253\u20131262. doi: 10.1212/wnl.0b013e3182309fa5.", "ArticleIdList": ["10.1212/wnl.0b013e3182309fa5", "PMC3179648", "21917766"]}, {"Citation": "Salloway S., Sperling R., Fox N.C., Blennow K., Klunk W., Raskind M. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014;370(4):322\u2013333. doi: 10.1056/NEJMoa1304839.", "ArticleIdList": ["10.1056/NEJMoa1304839", "PMC4159618", "24450891"]}, {"Citation": "Santos M.A. Recent developments on 3-hydroxy-4-pyridinones with respect to their clinical applications: mono and combined ligand approaches. Coord. Chem. Rev. 2008;252:1213\u20131224. doi: 10.1016/j.ccr.2008.01.033.", "ArticleIdList": ["10.1016/j.ccr.2008.01.033"]}, {"Citation": "Singh M., Kaur M., Kukreja H., Chugh R., Silakari O., Singh D. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur. J. Med. Chem. 2013;70:165\u2013188.", "ArticleIdList": ["24148993"]}, {"Citation": "Stark T., Lieblein T., Pohland M. Peptidomimetics that inhibit and partially reverse the aggregation of A\u03b21-42. Biochemistry. 2017;56:4840\u20134849.", "ArticleIdList": ["28841311"]}, {"Citation": "Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer\u2019s disease mitochondrial cascade hypothesis: progress and perspectives. Biochim. Biophys. Acta - Mol. Basis Dis. 2014;1842:1219\u20131231. doi: 10.1016/j.bbadis.2013.09.010.", "ArticleIdList": ["10.1016/j.bbadis.2013.09.010", "PMC3962811", "24071439"]}, {"Citation": "Tabet N. Acetylcholinesterase inhibitors for Alzheimer\u2019s disease: anti-inflammatories in acetylcholine clothing! Age Ageing. 2006;35:336\u2013338. doi: 10.1093/ageing/afl027.", "ArticleIdList": ["10.1093/ageing/afl027", "16788077"]}, {"Citation": "Tchantchou F., Lacor P.N., Cao Z., Lao L., Hou Y., Cui C. Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. J. Alzheimers Dis. 2009;18:787\u2013798. doi: 10.3233/jad-2009-1189.", "ArticleIdList": ["10.3233/jad-2009-1189", "19661619"]}, {"Citation": "Telpoukhovskaia, M.A., Patrick, B.O.C., Rod\u0155\u0131guezRod\u0155\u0131guez, Orvig, C., 2013. Exploring the multifunctionality of thioflavin- and deferiprone-based molecules as acetylcholinesterase inhibitors for potential application in Alzheimer's disease. Mol. BioSyst., 9, 792\u2013805. https://doi.org/10.1039/C3MB25600F", "ArticleIdList": ["23435553"]}, {"Citation": "Veldman E.R., Jia Z., Halldin C., Svedberg M.M. Amyloid binding properties of curcumin analogues in Alzheimer\u2019s disease postmortem brain tissue. Neurosci. Lett. 2016;630:183\u2013188. doi: 10.1016/j.neulet.2016.07.045.", "ArticleIdList": ["10.1016/j.neulet.2016.07.045", "27461789"]}, {"Citation": "Vellas B., Sol O., Snyder P.J. EHT0202 in Alzheimer\u2019s disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr. Alzheimer Res. 2011;8:203\u2013212. doi: 10.2174/156720511795256053.", "ArticleIdList": ["10.2174/156720511795256053", "21222604"]}, {"Citation": "Wagner M., Wolf S., Reischies F.M., Daerr M., Wolfsgruber S., Jessen F., Popp J., Maier W., Hull M., Frolich L., Hampel H., Perneczky R., Peters O., Jahn H., Luckhaus C., Gertz H.J., Schroder J., Pantel J., Lewczuk P., Kornhuber J., Wiltfang J. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology. 2012;78:379\u2013386. doi: 10.1212/WNL.0b013e318245f447.", "ArticleIdList": ["10.1212/WNL.0b013e318245f447", "22238414"]}, {"Citation": "Wang X., Sun G., Feng T., Zhang J., Huang X., Wang T. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression. Cell Res. 2019;29:787\u2013803. doi: 10.1038/s41422-019-0216-x.", "ArticleIdList": ["10.1038/s41422-019-0216-x", "PMC6796854", "31488882"]}, {"Citation": "Wisniewski T., Go\u00f1i F. Immunotherapeutic approaches for Alzheimer\u2019s disease. Neuron. 2015;85:1162\u20131176. doi: 10.1016/j.neuron.2014.12.064.", "ArticleIdList": ["10.1016/j.neuron.2014.12.064", "PMC4366618", "25789753"]}, {"Citation": "Yang T., Dang Y., Ostaszewski B. Target engagement in an Alzheimer trial: crenezumab lowers amyloid \u03b2 oligomers in cerebrospinal fluid. Ann. Neurol. 2019;86:215\u2013224. doi: 10.1002/ana.25513.", "ArticleIdList": ["10.1002/ana.25513", "PMC6771589", "31168802"]}, {"Citation": "Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005;280:5892\u20135901. doi: 10.1074/jbc.m404751200.", "ArticleIdList": ["10.1074/jbc.m404751200", "15590663"]}, {"Citation": "Yiannopoulou, K.G., Papageorgiou, S.G., 2020. Current and Future Treatments in Alzheimer Disease: An Update.\u00a0J Cent Nerv Syst Dis.12:1179573520907397. Published 2020 Feb 29. doi:10.1177/1179573520907397.", "ArticleIdList": ["PMC7050025", "32165850"]}, {"Citation": "Yiannopoulou K.G., Papageorgiou S.G. Current and future treatments for Alzheimer's disease. Ther. Adv. Neurol. Disord. 2013;6(1):19\u201333. doi: 10.1177/1756285612461679.", "ArticleIdList": ["10.1177/1756285612461679", "PMC3526946", "23277790"]}, {"Citation": "Zeng H., Chen Q., Zhao B. Genistein ameliorates beta-amyloid peptide (25\u201335)-induced hippocampal neuronal apoptosis. Free Radic. Biol. Med. 2004;36:180\u2013188. doi: 10.1016/j.freeradbiomed.2003.10.018.", "ArticleIdList": ["10.1016/j.freeradbiomed.2003.10.018", "14744630"]}, {"Citation": "Zhao X., Yuan L., Yu H., Xi Y., Ma W., Zhou X. Genistein inhibited amyloid-\u03b2 induced inflammatory damage in C6 glial cells. Arch. Med. Res. 2014;45:152\u2013157. doi: 10.1016/j.arcmed.2013.12.008.", "ArticleIdList": ["10.1016/j.arcmed.2013.12.008", "24480731"]}, {"Citation": "Zhou H., Liu J., Ren L., Liu W., Xing Q., Men L. Relationship between [corrected] spatial memory in diabetic rats and protein kinase C\u03b3, caveolin-1 in the hippocampus and neuroprotective effect of catalpol. Chin. Med. J. (Engl). 2014;127:916\u2013923. doi: 10.3760/cma.j.issn.0366-6999.20132137.", "ArticleIdList": ["10.3760/cma.j.issn.0366-6999.20132137", "24571888"]}, {"Citation": "Zhu F., Qian C. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer\u2019s disease. BMC Neurosci. 2006;7:78. doi: 10.1186/1471-2202-7-78.", "ArticleIdList": ["10.1186/1471-2202-7-78", "PMC1693919", "17137520"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "4", "Day": "7"}, {"Year": "2022", "Month": "10", "Day": "4"}, {"Year": "2023", "Month": "1", "Day": "5", "Hour": "2", "Minute": "34"}, {"Year": "2023", "Month": "1", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "1", "Day": "6", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "10", "Day": "12"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36601504", "PMC9805975", "10.1016/j.jsps.2022.10.004", "S1319-0164(22)00252-3"]}}], "PubmedBookArticle": []}